Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Chemo-immunotherapy for TNBC

Evandro de Azambuja • 20 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Checkpoint Inhibitors Pembrolizumab

Evandro de Azambuja, MD, PhD, of the Institut Jules Bordet, Brussels, Belgium, discusses the use of immune checkpoint blockade therapy in combination with chemotherapy in triple-negative breast cancer patients as well as the relative importance of PD-L1 expression status in patient stratification. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Evandro de Azambuja

2:01
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer
Evandro de Azambuja • 12 Sep 2022
1:14
Prognostic value of beta-2 adrenergic receptor levels in HER2+ breast cancer
Evandro de Azambuja • 12 Sep 2022
6:09
Adjuvant endocrine therapy for breast cancer: optimal durations and regimens
Evandro de Azambuja • 12 Sep 2022
2:06
NGS multi-panel gene testing for newly diagnosed patients with metastatic breast cancer
Evandro de Azambuja • 18 Sep 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals